Peripheral neuropathy and nerve electrophysiological changes with enfortumab vedotin in patients with advanced urothelial carcinoma: a prospective multicenter cohort study
Sign Up to like & getrecommendations! Published in 2024 at "International Journal of Clinical Oncology"
DOI: 10.1007/s10147-024-02481-8
Abstract: Enfortumab vedotin is a novel antibody–drug conjugate used as a third-line therapy for the treatment of urothelial cancer. We aimed to elucidate the effect of enfortumab vedotin-related peripheral neuropathy on its efficacy and whether enfortumab… read more here.
Keywords: electrophysiological changes; enfortumab vedotin; nerve; prospective multicenter ... See more keywords
Tisotumab Vedotin: First Approval
Sign Up to like & getrecommendations! Published in 2021 at "Drugs"
DOI: 10.1007/s40265-021-01633-8
Abstract: Tisotumab vedotin (Tivdak™) is an antibody-drug conjugate comprising a fully human monoclonal antibody specific for tissue factor (TF-011) conjugated to monomethyl auristatin E (MMAE) that has been engineered to target tissue factor expressing tumours. Based… read more here.
Keywords: tisotumab vedotin; vedotin; first approval; vedotin first ... See more keywords
Pharmacovigilance study of the association between peripheral neuropathy and antibody–drug conjugates using the FDA adverse event reporting system
Sign Up to like & getrecommendations! Published in 2024 at "Scientific Reports"
DOI: 10.1038/s41598-024-71977-0
Abstract: Antibody–drug conjugates (ADCs) are among the fastest-growing classes of anticancer drugs, making it crucial to evaluate their potential for causing peripheral neuropathy. We analyzed data from the FAERS database (January 1, 2014, to June 30,… read more here.
Keywords: antibody drug; vedotin; study; drug conjugates ... See more keywords
Efficacy of modified enfortumab vedotin ineligible criteria (mEVITA) in advanced urothelial carcinoma
Sign Up to like & getrecommendations! Published in 2025 at "Scientific Reports"
DOI: 10.1038/s41598-025-09806-1
Abstract: Enfortumab Vedotin Ineligible criTeriA (EVITA) were proposed for the selection of patients to receive enfortumab vedotin (EV) and pembrolizumab treatment. However, the usefulness of these criteria has not been fully verified. We retrospectively analyzed data… read more here.
Keywords: urothelial carcinoma; ineligible criteria; enfortumab vedotin; vedotin ineligible ... See more keywords
Risk of adverse events in lymphoma patients treated with brentuximab vedotin: a systematic review and meta-analysis
Sign Up to like & getrecommendations! Published in 2020 at "Expert Opinion on Drug Safety"
DOI: 10.1080/14740338.2020.1718103
Abstract: ABSTRACT Objectives: To assess the risk of adverse events (AEs) associated with brentuximab vedotin in lymphoma patients. Methods: Articles were retrieved from PubMed, Cochrane, and Clinicaltrials Databases to identify randomized controlled trials (RCTs) comparing brentuximab… read more here.
Keywords: brentuximab vedotin; vedotin; risk adverse; lymphoma patients ... See more keywords
Inhibition of MDR1 Overcomes Resistance to Brentuximab Vedotin in Hodgkin Lymphoma
Sign Up to like & getrecommendations! Published in 2019 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-19-1768
Abstract: Purpose: In classical Hodgkin lymphoma, the malignant Reed–Sternberg cells express the cell surface marker CD30. Brentuximab vedotin is an antibody–drug conjugate (ADC) that selectively delivers a potent cytotoxic agent, monomethyl auristatin E (MMAE), to CD30-positive… read more here.
Keywords: hodgkin lymphoma; brentuximab vedotin; vedotin; resistance ... See more keywords
Abstract 1909: Advancing a novel tubulin-inhibitor ADC technology: The Adcentrx auristatin platform offers enhanced efficacy and safety profiles compared to vedotin technology
Sign Up to like & getrecommendations! Published in 2024 at "Cancer Research"
DOI: 10.1158/1538-7445.am2024-1909
Abstract: Auristatins represent an important class of anti-mitotic antibody-drug conjugate (ADC) payloads with potent cytotoxic effects on rapidly dividing cancer cells. Most notably, monomethyl auristatin E (MMAE) stands as the most extensively validated compound, laying the… read more here.
Keywords: technology; auristatin; efficacy; vedotin ... See more keywords
Abstract 3133: PF-08046032: a CD25-directed vedotin ADC leveraging a well characterized safety and pharmacokinetic profile for enhanced regulatory T cell depletion in the tumor microenvironment
Sign Up to like & getrecommendations! Published in 2025 at "Cancer Research"
DOI: 10.1158/1538-7445.am2025-3133
Abstract: PF-08046032 is a novel vedotin antibody-drug conjugate (ADC) engineered to target and deplete immunosuppressive regulatory T cells (Tregs) within the tumor microenvironment (TME) through direct cytotoxicity. PF-08046032 directs delivery of the cytotoxic MMAE (monomethyl auristatin… read more here.
Keywords: cd25; adc; tumor; vedotin ... See more keywords
A review of the novel tissue factor antibody–drug conjugate: Tisotumab vedotin
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Oncology Pharmacy Practice"
DOI: 10.1177/10781552221139775
Abstract: Objective To review and compare the pharmacology, efficacy, and safety of the novel tissue factor antibody–drug conjugate, tisotumab vedotin Data sources Literature search was performed through PubMed MEDLINE, Google Scholar, ClinicalTrials.gov, and the Food and… read more here.
Keywords: novel tissue; tissue factor; vedotin; drug ... See more keywords
Phase 2 trial of ozuriftamab vedotin (BA3021), a conditionally binding ROR2-ADC, in patients with heavily pretreated squamous cell carcinoma of the head and neck.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.16_suppl.6048
Abstract: 6048 Background: Recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) represents a marked unmet need. ROR2 is a cell-surface transmembrane receptor protein tyrosine kinase highly expressed in several tumor types… read more here.
Keywords: phase trial; ozuriftamab vedotin; vedotin; binding ror2 ... See more keywords
Hereditary Neuropathy with Liability to Pressure Palsies Unmasked by Polatuzumab Vedotin-containing Chemotherapy.
Sign Up to like & getrecommendations! Published in 2025 at "Internal medicine"
DOI: 10.2169/internalmedicine.6361-25
Abstract: We report the case of a 49-year-old man with hereditary neuropathy with liability to pressure palsies unmasked by polatuzumab vedotin-containing chemotherapy. Neuropathic symptoms were predominant in areas surrounding the right and left ulnar nerves after… read more here.
Keywords: liability pressure; chemotherapy; polatuzumab vedotin; vedotin ... See more keywords